Nexgel (NXGLW) Cost of Revenue (2018 - 2025)

Nexgel has reported Cost of Revenue for 8 years, with the latest figure at $2.0 million in Q4 2025.

• For the quarter ending Q4 2025, Cost of Revenue rose 0.51% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $6.9 million (up 15.1% YoY), and the FY2025 full-year result was $6.9 million, up 16.36% from the prior year.
• Cost of Revenue for Q4 2025 stood at $2.0 million, up from $1.7 million in the prior quarter.
• The five-year high for Cost of Revenue was $2.0 million in Q4 2025, with the low at $309000.0 in Q1 2021.
• Historically, Cost of Revenue has averaged $998100.0 across 5 years, with a median of $934500.0 in 2023.
• Annual changes were most pronounced in 2023 — Cost of Revenue surged 139.55% — and 2025, when it decreased 5.27%.
• Nexgel's Cost of Revenue stood at $430000.0 in 2021, then gained by 13.49% to $488000.0 in 2022, then soared by 139.55% to $1.2 million in 2023, then jumped by 68.26% to $2.0 million in 2024, then advanced by 0.51% to $2.0 million in 2025.
• The last three Cost of Revenue figures came in at $2.0 million (Q4 2025), $1.7 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.